381 related articles for article (PubMed ID: 15544627)
1. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
2. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
3. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
4. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
5. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
6. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
7. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
8. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
Rogers A; Eastell R
J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
10. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
[TBL] [Abstract][Full Text] [Related]
11. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
12. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
13. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
14. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
16. Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand.
Ziegler S; Niessner A; Richter B; Wirth S; Billensteiner E; Woloszczuk W; Slany J; Geyer G
Metabolism; 2005 Jul; 54(7):935-8. PubMed ID: 15988704
[TBL] [Abstract][Full Text] [Related]
17. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
[TBL] [Abstract][Full Text] [Related]
18. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss.
Moschen AR; Kaser A; Enrich B; Ludwiczek O; Gabriel M; Obrist P; Wolf AM; Tilg H
Gut; 2005 Apr; 54(4):479-87. PubMed ID: 15753532
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts.
Hormdee D; Nagasawa T; Kiji M; Yashiro R; Kobayashi H; Koshy G; Noguchi K; Nitta H; Ishikawa I
Clin Exp Immunol; 2005 Dec; 142(3):490-7. PubMed ID: 16297161
[TBL] [Abstract][Full Text] [Related]
20. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]